Peptide-Based Vaccines: Current Progress and Future Challenges
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Gene and Cell Therapy".
Deadline for manuscript submissions: closed (20 June 2023) | Viewed by 357
Special Issue Editors
Interests: human infectious diseases; viral infections; B- and T-cell immunology; vaccine/therapeutic development; mouse model development
Special Issues, Collections and Topics in MDPI journals
Interests: autoimmunity; vaccine; chemotherapeutic; T-cells; parasites; leishmaniasis; malaria; drug development
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Vaccines are perhaps the most successful discovery of biomedical sciences, and prevent approximately 2–3 million deaths annually. Representing a step forward, peptide-based vaccines have revolutionized disease management and prevention against various infectious diseases, including viral, bacterial, fungal, and parasitic diseases. They have also gained researchers’ interest regarding the prevention, rather than treatment, of other chronic diseases such as cancer and Alzheimer’s disease. Peptide-based vaccines (also called subunit vaccines) consist of immunogenic components of infectious agents or disease-associated epitopes. These vaccines aim to impart protective immunity with prior exposure of pathogen-specific epitopes to the host’s protective immune cells. The major challenge is to find a pathogen-specific epitope that could direct the immune response against the pathogen. In contrast, while developing vaccines against self-antigens to cure various chronic and autoimmune diseases, the immune system plays a crucial role in suppressing response to self-antigens. This Special Issue invites quality research works exploring peptide-based vaccine development against infectious, chronic, and autoimmune diseases for publication.
Dr. Shailendra Kumar Verma
Dr. Rajan Kumar Pandey
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- subunit vaccine
- immunoinformatics
- immunogenic vaccines
- peptide-based vaccines
- B-cell epitopes
- T-cell epitopes
- adjuvant
- chronic infection
- autoimmune diseases humoral response
- cell-mediated response
